News · via Entrackr

Redcliffe Labs buys Pune’s Megavision for Rs 40 Cr

Redcliffe Labs has acquired Pune-based Megavision Diagnostics for about Rs 40 crore, adding two MRI-equipped imaging centres to a network built on pathology. The company says the existing workforce will be retained.

The signal
  • Redcliffe Labs acquired Pune-based Megavision Diagnostics for about Rs 40 crore.
  • Megavision runs 2 MRI-equipped imaging centres in Pune, and its workforce will be retained after the deal.
  • Redcliffe says it operates 80 plus owned laboratories across 220 plus cities, covers 4,000 plus pincodes and offers 3,600 plus tests.
  • Redcliffe says it has served over 1 crore customers; the report discloses no revenue for either company and does not specify cash or stock.

Redcliffe Labs has acquired Megavision Diagnostics, a Pune-based diagnostics centre focused on imaging, for about Rs 40 crore. Megavision runs two MRI-equipped centres in Pune. Redcliffe said the existing workforce will be retained. The report does not specify whether the consideration is cash, stock or a mix.

Redcliffe framed the deal as a way to bring imaging and pathology under a single platform and to widen its geographic presence. The company says it operates 80 plus owned laboratories across 220 plus cities, covers 4,000 plus pincodes and offers 3,600 plus diagnostic tests, having served over 1 crore customers to date. No revenue figures were disclosed for either side, and no executives were quoted. The report places the deal within broader consolidation, with diagnostic chains using acquisitions to add geography and capability.

At about Rs 40 crore for two centres, the implied price is roughly Rs 20 crore per site. With no revenue disclosed for Megavision, there is nothing in the report to test that against.

The structural point is the asset shift. Pathology at Redcliffe’s scale is a routing business: collection agents, cold chain, pincode coverage and labs that process samples in batches. Capacity is added by hiring and by opening collection points. Imaging is the opposite. An MRI is a fixed, expensive machine tied to one address, and the economics turn on scanner utilisation per day. Buying two of them is not a bolt-on to a distribution network. It is a second business model with its own capacity ceiling and its own depreciation.

For anyone selling health direct to consumers in India, the read is on the cross-sell surface. Pathology is a repeat, low-ticket purchase. Imaging is infrequent and high-ticket. Holding both under one login lets a diagnostics platform move a customer from a routine blood panel to a scan without handing them to a third party, and it builds a longitudinal record that no single-service rival holds. That record, more than the two Pune centres, is the durable part of what Rs 40 crore buys.

Source

Zane’s analysis draws on original reporting by Entrackr. Read the original report.

The daily brief

Beat the market open

What moved Indian commerce, every morning.

One email a day. No spam, ever.

Related insights

More news

India's Commerce Engine

Read the news,
then act on it.

hello@zane.marketing

Book a meeting